Treatment Medicine
Treatment
Medical treatment studies of brain fatigue have been limited, and only a few drugs have been evaluated. Here, we briefly report on our experience with two drugs. Future research can hopefully provide more knowledge about treatment options. More detailed information about our studies can be found in the published research articles (see further under Research).
Methylphenidate
For approximately six years, we have worked on a research project studying methylphenidate treatment in people suffering from brain fatigue following a traumatic brain injury. We cannot comment on its effectiveness for other diseases or conditions.
A careful medical assessment must always be made before starting the treatment. There are diseases and conditions where methylphenidate is not appropriate. Treatment requires solid experience and close contact with the patient.
When the treatment produces a positive effect, brain fatigue can be alleviated, enhancing the patient’s well-being and cognitive function. Although no increase in working hours was feasible, many reported that they could continue to work at a certain level and participate in social activities. It is important to remember that methylphenidate does not work for everyone, and an individualized dosage is crucial.
Methylphenidate is not a cure for brain fatigue. A lack of energy will remain, even if at a lower level. The person must continue to use energy-saving strategies.
Treatment with methylphenidate, when brain fatigue becomes prolonged or chronic, should not produce side effects but enhance quality of life. Therefore, adjusting the individual dose and careful follow-up of the patient is very important.
It is noteworthy that methylphenidate is currently the only approved treatment for ADHD/ADD. More research is needed before methylphenidate can be used for brain fatigue.
The Dopamine Stabilizer OSU6162
In two studies, one pilot study and one follow-up study, we investigated the effect of OSU6162 (not available on the market) for brain fatigue. Half of the participants suffered from brain fatigue after a traumatic brain injury and half after a stroke. Brain fatigue was the participants’ central concern. We found that it is possible to reduce brain fatigue for some, but it did not work for everyone. OSU6162 appears to be a milder substance compared to methylphenidate.